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Abstract. Purpose: The first aim of the study was to
investigate the diagnostic potential of 11C-acetate PET in
the early detection of prostate cancer recurrence. A second
aim was the evaluation of early and late PET in this
context.
Methods: The study population comprised 32 prostate
cancer patients with early evidence of relapse after initial
radiotherapy (group A) or radical surgery (group B). The
median PSA of group A (n=17) patients was 6 ng/ml
(range 2.6–30.2) while that of group B (n=15) was 0.4 ng/
ml (range 0.08–4.8). Pelvic-abdominal-thoracic PET was
started 2 min after injection of 11C-acetate and evaluated
after fusion with CT.
Results: Group A: Taking a SUVmax≥2 as the cut-off, PET
showed local recurrences in 14/17 patients and two
equivocal results. Distant disease was observed in six
patients and an equivocal result was obtained in one.
Endorectal MRI was positive in 12/12 patients. Biopsy
confirmed local recurrence in six of six (100%) patients.
PET was positive in five of the six patients with biopsy-
proven recurrences, the result in the remaining patient
being equivocal. Group B: Among the 15 patients, visual
interpretation was positive for local recurrences in five
patients and equivocal in four. One obturator lymph node
was positive. Endorectal MRI was positive in 11/15
patients and equivocal in two. Positional correlation of
positive/equivocal results on PET and endorectal MRI was
observed in seven of nine patients. PSA decreased
significantly after salvage radiotherapy in 8/14 patients,
providing strong evidence for local recurrence. PET of the
eight patients responding to RT was positive in three and
equivocal in two.
Conclusion: 11C-acetate PET was found to be valuable in
the early evaluation of prostate cancer relapse. Optimising
scanning time and use of modern PET-CT equipment
might allow further improvement.
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Introduction
Conventional radiology of recurrent prostate cancer has a
low sensitivity and specificity because of difficulties in
differentiating between recurrent tumour and repair tissue
after surgery and/or radiation therapy (RT).18F-fluoro-
deoxyglucose positron emission tomography (FDG-PET)
also has a low sensitivity owing to the modest glucose
consumption of these tumours and the proximity of the
urinary tract, with high background activity [1, 2].
Promising results in the detection of recurrent prostate
cancer have been obtained with the newer PET tracers 11C-
acetate, 11C-choline and 18F-fluorocholine [3–7]. Radio-
labelled acetate and choline are partially integrated as
phosphatidylcholines into the cellular membranes of
proliferating cells, another part being catabolised [8].
PET with these tracers could thus show biological
functionality of radiologically suspicious lesions.
Recently, nanoparticle-enhanced magnetic resonance
imaging (MRI) has emerged, yielding encouraging results
[9, 10]. Endorectal MRI could provide the most interesting
information concerning local disease [11, 12], notably in
distinguishing T2 and T3 stages [13]. However, the
interpretation following radiotherapy remains challenging
owing to the difficulty in differentiating between post-RT
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signal modifications and tumour relapse [14]. In the latter
situation, a higher specificity has been described for MR
spectroscopy [14] than for endorectal MRI.
Independent of the radiological evaluations, tumour
relapse is, as would be expected, more frequent in high-risk
prostate cancer patients. A consensus statement of the
American Joint Committee on Cancer (AJCC) defined
advanced T staging (T ≥pT2c), high tumour grades (sum of
Gleason score ≥8) and high pre-surgical serum prostate-
specific antigen (PSA) values (>20 ng/ml) as the three
major risk parameters of prostate cancer [15]. Positive
surgical margins, seminal vesicle invasion and capsular
involvement represent further risk parameters [16–18].
Several of the initial 11C-acetate or 11C- or 18F-choline
PET studies [3–7] were performed in patients with rather
high PSA values, suggestive of advanced disease. A more
significant contribution for patient management might be
expected from PET performed at earlier stages of tumour
recurrence. However, a first evaluation of 11C-acetate PET
showed a low sensitivity of only 7% in post-surgical
patients with PSA values below 3.0 ng/ml [4].
Definition of biochemical recurrence is clearly different
after initial radical surgery or radiotherapy. Radical surgery
eliminates all prostate tissue and PSA is expected to fall
below the detection limit. Thus, recurrence in these patients
is already suspected at the earliest rise in PSA [19–21]. It
has been shown that even very low PSA values of 0.1–
0.2 ng/ml following radical surgery represent a probability
for further rise in PSA and tumour recurrence of 90% [22].
The risk would be 67% at PSAvalues ≤0.1 ng/ml according
to this study [22].
Regarding patients with first-line RT, definition of
recurrence by reference to rising PSA remains a matter of
debate. An ASTRO consensus statement of 1997 required
the measurement of three consecutive increases in PSA
[23]. More recently, a retrospective analysis of 4,800
patients [24] showed that other definitions of recurrence
would be slightly more sensitive and specific than the
ASTRO criterion. After RT, measurement of two con-
secutive PSA increases of at least 0.5 ng/ml each, or a PSA
value ≥2 ng/ml above nadir, would provide sensitivities
and specificities for recurrence of between 64% and 78%
[24]. Considering these rather modest results for sensitivity
and specificity, it is obvious that the definition of treatment
failure following RT remains difficult. A strong suspicion
of recurrence will generally be established at PSA values
significantly higher than 2 ng/ml.
Salvage RT of post-surgical patients with recurrent
cancer has been studied by different groups. It has been
shown that a PSAvalue >2 ng/ml is a bad prognostic factor
[25]. Accordingly, salvage RTshould be performed as early
as possible. As a challenge for PET, the most interesting
patient population in the post-surgical situation would
therefore present very low PSA values. Tumour size in
these patients will be particularly small and PET partial
volume effects will be frequently observed. As a
consequence, the predictive value of the standardised
uptake value (SUV) in these patients might be compro-
mised. As mentioned, a first evaluation of 11C-acetate PET
in post-surgical patients with PSA values below 3 ng/ml
showed a disappointingly low sensitivity [4]. A commen-
tary questioned the methodology of this study, such as the
absence of SUV measurement and the low number of
histological confirmations [26].
The first aim of the present study was to investigate the
diagnostic potential of 11C-acetate PET in the early
detection of prostate cancer recurrence. Patients were
studied at biochemical relapse after initial RT (group A) or
radical surgery (group B). Based on the above-mentioned
considerations, SUVmax, though calculated for all areas of
focal uptake, was not used in the PET interpretation of
patients from group B.
A second aim was the evaluation of early and late PET.
In fact, while several studies have suggested that tumour
uptake of 11C-acetate is very rapid [7, 27], the retention
time in tumours of individual patients has not been
described. Late PET was performed with the intention of
ascertaining whether individual tumours remained positive.
Materials and methods
Patient population
All patients gave their written informed consent to the study protocol,
which had been approved by the ethical commission of the hospital
and the Swiss authorities (Swissmedic and Federal Office of Public
Health, Section of Radioprotection). The consecutive PET studies
presented here were performed from December 2004 to July 2005.
Two groups were evaluated. Patients of group A (n=17) had been
treated initially with RT. Table 1 summarises their clinical status and
their biochemical status initially and at PET. Median tumour
radiation dose was 74 Gy (range 64–78.4 Gy). Nine (53%) of the
17 patients presented one or more of the three high-risk factors as
previously described [15]. The rise in PSA after nadir post RT was
significant and confirmed at least once.
Patients of group B (n=15, numbered 18–32) were treated
initially with radical surgery. Table 2 summarises their clinical status
and their biochemical status initially and at PET. All 15 patients
presented one or more of the three high-risk factors [15]. Many
patients of this group presented further risk factors [16–18], such as
histologically positive surgical margins (n=11), invasion of seminal
vesicles (n=4), capsular invasion (n=9) or perineural invasion
(n=13).
11C-acetate
11C-acetate was prepared at the cyclotron unit of Geneva University
Hospital from 11C-carbon dioxide produced on an IBA 18/9
cyclotron, according to a modified [28], previously published
procedure [29]. In brief, 11C-acetate was prepared based on a
combination of the captive solvent radiolabelling “Grignard” reac-
tion [30] conducted in the sterile catheter extension tube, followed by
the convenient solid-phase extraction purification [29] on a series of
ion-exchange cartridges. The requested radiochemical purity of the
patient formulations, as determined by high-performance liquid
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chromatography, was ≥95%. Mean radiochemical purity of 11C-
acetate at injection was 98.2±1.6%.
PET, CT and fusion
The PET scanner used was the ECATART (Siemens/CTI, Knoxville,
TN, USA). After bladder voiding, patients were placed in the
scanning position and six-run transmission scanning (5 min/bed
position) using 137Cs single-photon point sources was recorded
starting at the prostate bed. The laser-defined starting position was
marked in ink on the patient’s leg. Patients were then injected,
applying standard precautions, with an activity of 520 MBq 11C-
acetate. This activity was selected in order to cover the long scanning
time of a trunk scan as performed here. The emission scan was started
2 min after acetate injection, comparable with previous studies [7,
27]. The initial run of 10 min was centred on the prostate bed,
followed by five runs of seven minutes each covering the rest of the
pelvis, abdomen and thorax. A final run of 10 min, started at 47 min
post injection, was again again on the prostate bed.
In a typical PET scan and for a patient injected with 520 MBq
11C-acetate, the number of trues per bed position was about 12–
18×106 counts on the first six runs and about 8×106 counts on the
final prostate bed-centred run. The initial modest number of trues per
time unit reflects the low sensitivity of the partial-ring tomograph and
its low count rate performance for the relatively high activity injected
since the peak noise equivalent count rate for a 20-cm-diameter
cylinder is 27 kcps at a concentration of 15 kBq/ml [31]. It should be
emphasised that the performance of the camera can be improved by
operating the scanner with a decreased block integration time and
reduced coincidence time window [32].
CT imaging was performed between 2 and 48 h after the PETscan
on a Siemens Sensation 16 scanner. The starting position of the
dedicated fusion CT, marked with two metallic needles, was identical
to that of the PETscan (ink marks), as verified by the same physician.
PET-CT image fusion in the first four patients used the standard
contrast-enhanced thoracic-abdominal-pelvic CT. It showed the
major difficulties in the alignment of PET and CT data acquired in
different scanning positions and with different breathing. Subse-
quently, patients had a non-contrast-enhanced CT for image fusion
acquired in the PET position (arms held along the body) and with flat
breathing. The non-contrast-enhanced CT was finally modified to a
low-dose CT [33] in the PET position and flat breathing using
120 kV, 60 mAs and a pitch of 1.5 and a 1-s rotation. Under the latter
condition, the mean effective radiation dose for an adult patient was
3.5 mSv, as calculated using the IMPACT CT patient dosimetry
calculator (http://www.impactscan.org/ctdosimetry.htm).
PET images were reconstructed using iterative attenuation-
weighted ordered subset expectation maximisation (OSEM). An
attenuation correction matrix was calculated by segmenting the
attenuation map, followed by forward projection at appropriate
angles of the transmission image [34]. The generated attenuation
correction map was used to reconstruct the emission data. The
images were scatter corrected and reconstructed by using normalised
attenuation-weighted, OSEM iterative reconstruction implemented
with the ECAT 7.2 software. The default parameters used were
OSEM iterative reconstruction with two iterations and eight subsets
followed by a post-processing Gaussian filter (kernel full-width half-
maximal height, 6 mm). The voxel size was set to 3.4×3.4×3.4 mm3.
Attenuation-corrected views were obtained in transaxial, coronal and
sagittal planes.
One of the surgically treated patients (patient 26) had a hip
prosthesis that led to a CT artefact projecting on the prostate bed. His
PET/CT fusion scan was therefore analysed without and with
attenuation correction. All other patients had their attenuation-
corrected PET/CT fusion scan evaluated.
PET to CT image co-registration was performed using the
commercial Hermes multi-modality fusion software (Nuclear Diag-
nostics AB, Stockholm, Sweden).
Standardised uptake values (SUV) were calculated [35] as
follows: SUV=lesion activity per gram/(injected activity/patient
body mass (g)). Mean and maximal SUV were calculated for ROIs
of focal uptake and compared with adequate control regions to derive
tumour to non-tumour (T/N) ratios.
A standard, contrast-enhanced CTwas available for all patients. It
was consulted for PET interpretation if suspicious foci of uptake in
the abdomino-pelvic region suggested the presence of adenopathies
or if other structures generated focal uptake, such as degenerative
osseous disease, and the low-dose CT did not present the necessary
resolution to allow their clear definition.
Table 1. Characteristics of 17 group A patients treated initially by
RT
Age (yrs)
Mean 72.5
Range 58–87
Initial stage
cT1 n=4
cT2a–b n=4
cT3a n=7
n.a. n=2
Gleason score
4–6 n=7
7 n=5
>7a n=2
n.a. n=3
Initial PSA (ng/ml)
<10 n=2
10–20 n=9
>20a n=4
n.a. n=2
Initial RT dose (Gy)
Mean 73.9
Range 64–78.4
PSA at PET (ng/ml)
Mean 10.4
Range 2.6–30.2
Median 6.0
PSA doubling time (months)
Mean 8.2
Range 1–24
Time from RT (months)
Mean 61.7
Range 27.5–100.7
aIndicates high-risk patient characteristics
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PET interpretation was performed by two experienced nuclear
medicine physicians who gave their final consensus statement in the
clinical report as tumour positive, equivocal or tumour negative.
Salvage RT and follow-up
Salvage RT in post-surgical patients was performed with 18 MV-X-
rays using a Clinac 2100-C linear accelerator and an irradiation
technique of four fields (anterior, posterior and two lateral). RT was
delivered in five weekly fractions of 2 Gy/day to a total of 32
fractions (64 Gy) directed on the prostate bed. A boost dose of five
fractions (10 Gy) was delivered to tumour recurrences, whenever
such a recurrence was shown by endorectal MRI and/or 11C-acetate
PET.
Provided there was an adequate interval from initial RT and
absence of distant disease in patients of group A, in these patients a
second, salvage RTwas proposed after hormonal therapy. Secondary
salvage RT used 18-MV X-rays generated by the Clinac 2100-C
linear accelerator and administered using the standard protocol of 5×
weekly at 1.8 Gy/day up to 45 Gy (25 fractions). External beam RT
was then completed with 18 Gy brachytherapy.
All included patients accepted the complementary evaluation
with endorectal MRI and a diagnostic contrast-enhanced thoraco-
abdominal-pelvic CT. Bone scintigraphy was performed in eight
patients of group A and in seven patients of group B.
Patients of group A had various further evaluations. Biopsies as
the gold standard for local disease were indicated prior to salvage RT
in the absence of evidence of systemic disease. Endorectal MRI was
performed in 12 patients and completed with MR spectroscopy in
nine [14]. Patients with disseminated disease as shown by radiology
received hormonal therapy alone.
Patients who had undergone initial radical surgery were proposed
salvage RT based on their situation of high-risk prostate cancer in the
absence of evidence, with the exception of a single positive obturator
lymph node in one patient, of dissemination both at initial surgery
and at relapse. One patient of this group with a particularly
aggressive tumour (Gleason 5+5) was initially given anti-hormonal
treatment, followed by salvage RT.
Response to salvage RT was taken as a safe indication for local
relapse. Thus, a reduction in the PSA value by ≥50% 6 weeks after
completion of RT, compared with the initial value, served as
surrogate proof for the presence of tumour. Biochemical response
after salvage RT, whereby PSA values had decreased to less than
0.04 ng/ml (detection limit), indicated an optimal local response,
providing the strongest evidence for the presence of localised disease
alone.
Statistical analysis
For evaluation of the statistical correlation between early and late
prostate PET, the inter-category variation kappa test was performed
Table 2. Characteristics of 15 group B patients treated initially by radical surgery
Patient Age
(yrs)
Stage Gleason
score
PSA initial/after
surgery(ng/ml)
Surgical
margins
Infiltrations PSA doubling
time (months)
Time from
surgery (months)
PSA at PET
(ng/ml)
18 48 pT3ba 3+4 79.5a /0.5 Neg. Perineural, seminal
vesicle
7 18.3 2.4
19 70 pT3aa 4+3 8.5/0.11 Pos. Perineural, capsular,
vascular
1 10.0 3.6
20 68 pT3aa 3+4 10.5/0.05 Pos. Perineural, capsular 15 47.7 0.76
21 62 pT3aa 3+4 7.8/<0.1 Neg Perineural, capsular 6 34.0 0.33
22 64 pT3aa 4+3 n.a./0.2 Pos. Perineural 30 71.8 4.8
23 63 pT2ca 3+3 13.2/0.06 Pos. Perineural 12 24.1 0.26
24 73 pT3aa 3+4 9.1/0.05 Neg. Perineural, capsular 24 52.4 0.3
25 73 pT3ba 3+3 10/0.24 Pos. Perineural, capsular,
seminal vesicle
Postop. 3.0 0.24
26 55 pT2b 9a 6.2/0.9 NA NA 12 52.0 3.10
27 65 pT3aa 4+5a 33.2a /0.36 Pos. Perineural Postop. 5.0 0.40
28 71 pT3ba 4+3 7.1/<0.04 Pos. Perineural, capsular,
seminal vesicle
12 27.3 0.08
29 63 pT3ba 5+5a 6.3/0.51 Pos. Perineural, capsular,
seminal vesicle
Postop. 3.1 0.51
30 67 pT3aa 4+3 4.9/0.05 Pos. Perineural, capsular 2 7.0 0.19
31 70 pT3aa 3+4 5.5/<0.04 Pos. Perineural, capsular 8 14.0 0.20
32 66 pT2b 3+3 23.0a /0.19 Pos. Neg. 36 44.4 0.39
Mean 65.2 7.3 16.1/0.22 13.8 27.6 1.17
SD 6.7 1.2 19.9/0.25 10.9 21.8 1.52
Median 66.0 7.0 8.8/0.11 12.0 24.1 0.39
Neg. negative, Pos. positive, NA not available, Postop. postoperative
aIndicates high-risk patient characteristics
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using the UNISTAT 5.5 statistical package for Windows (2002
edition, Unistat Ltd, London, England, run on Windows XP)
comparing positive, suspicious and negative results. Ap value <0.05
was considered significant. Un-weighted kappa values of 0.01–0.19,
0.2–0.39, 0.4–0.59, 0.6–0.79 and 0.8–1.0 were rated as slight, fair,
moderate, substantial and almost perfect agreement, respectively [36].
Results
All 11C-acetate injections (518±18 MBq, radiochemical
purity 98.2±1.6%) were well tolerated.
The principal characteristics of the 17 patients in group
A, treated initially with RT, are summarised in Table 1.
Nine patients (53%) presented one or more high risk
factors. The rise in PSA in these patients was significant,
reaching a median value of 6 ng/ml at PET. The median
delay between initial radiotherapy and PET was
61.7 months.
The characteristics of the 15 patients in group B are
presented in Table 2. All were at high risk, presenting one
or more of the three major risk determinants according to
the consensus statement (Table 2). Eleven patients had
histologically positive surgical margins, highly suggestive
of residual local disease. Twelve patients had a confirmed
increase in PSA observed 7–52 months after surgery. The
three other patients underwent the 11C-acetate PET
between 3 and 5 months post radical surgery based on a
PSA that did not return to baseline but remained elevated at
between 0.24 and 0.51 ng/ml. These elevated values were
confirmed before salvage RT. The median delay between
surgery and PET was 24.1 months, and a median PSA of
0.4 ng/ml was measured within 1 month of PET. PSAwas
below 0.8 ng/ml in 11 of 15 patients.
PET in patients treated initially with RT
In group A, focal uptake with an SUVmax≥2 were
considered abnormal. Focal uptake <2 was considered
equivocal. According to these criteria, 14 patients (82%)
were positive (Figs. 1, 2) and two (12%) equivocal for local
recurrence. Mean SUVmax of positive and equivocal results
was 2.9 and the mean T/N ratio was 2.4 (Table 3).
With regard to lymph node disease, five patients showed
focal 11C-acetate uptake. In detail, three patients had lymph
nodes with a SUVmax higher than 2.0, another patient had
one node that was clearly positive and one that was
equivocal, and one patient had one equivocal result. In
comparison with CT, three patients (patients 2, 3 and 9) had
positive or equivocal 11C-acetate PET for adenopathies as
defined by CT with lymph node diameters ≥1 cm. Two
patients had a positive or equivocal PET scan (patients 16
and 13, respectively) for lymph nodes smaller than 1 cm in
diameter that were not considered suspicious on the basis
of radiological criteria.
With regard to M staging, a biopsy-proven metastasis of
the corpus cavernosum was highly positive on PET
(SUVmax 6.3). Contrast-enhanced CT, performed in all
patients, and bone scintigraphy, performed in eight
patients, were positive or suspicious for bone metastases
in four patients. However, only two of the multiple
vertebral metastases were rated positive by PET (in patient
15) while three suspicious lesions of the ribs and two
lumbar vertebrae were negative on PET. One suspicious
lesion of the skull was outside the PET scanning field.
At late pelvic PET, following the observation of
decreasing SUVmax of initially positive lesions, a positive
cut-off level of 1.5 was used. Late PET of the prostate bed
Fig. 1. 11C-acetate PET of patient 8 performed 30 months post RT.
PSA before RT combined with hormonal therapy was 21.8 ng/ml
and it fell to 0.3 ng/ml after treatment. PSA later rose rapidly to
8.0 ng/ml at PET, with a short doubling time of 2 months. PET scan
at seminal vesicle level (a) is shown, together with the correspond-
ing fused imaging (b) and CT (c). Note the focal uptake on the right,
with a SUVmax of 2.0, and a smaller focus on the left. Endorectal
MRI (not shown) completed with MR spectroscopy showed an
extended lesion infiltrating bilaterally into the seminal vesicles
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was positive for local recurrence in 13 patients (77%) and
equivocal in three (18%). The mean SUVmax of positive/
equivocal results was 2.0±0.7 and the mean T/N ratio,
2.3±0.6. When analysing early and late PET for correlation
of positive, equivocal and negative results of local
recurrence, concordance (p<0.05) was observed but
kappa was moderate, with a value of 0.49.
Endorectal MRI was performed in 12 patients and
completed with MR spectroscopy in nine. It indicated the
presence of local recurrence(s) in all evaluated patients.
Definitive confirmation by histology (the gold standard
for the presence of local disease) was indicated in patients
who presented evidence of exclusive local recurrence.
Biopsies were obtained from six patients and were all
positive (100%). In comparison to initial grading, the
Gleason score remained identical in three patients and
increased by 1 point in the other three.
With regard to biopsy-proven recurrences (n=6), PET
was positive in five of these patients and equivocal in one.
PET in surgically treated patients
The prostate bed of patients of group B was assumed to be
empty of any prostate tissue after initial radical surgery.
Furthermore, the interval between surgery and PET was
long, at 3 months or more. Any post-surgical inflammatory
response was therefore expected to have disappeared.
Furthermore, the very low PSA values in many of these
patients indicated the presence of very small tumour
recurrences/residues. This hypothesis was supported by
endorectal MRI, which showed the prevalence of fre-
quently single, small tumour lesions. For these reasons, the
SUVmax values, while determined, were not used in the
interpretation of the PET scan, since partial volume effects
would artificially diminish these values.
Reading of the attenuation-corrected PET/CT fusion
scans revealed five positive (Figs. 3, 4) and four equivocal
results for local recurrence (Table 4). A single lymph node
of the obturator region was interpreted as positive in patient
32, its SUVmax being 2.6. No further metastasis was
detected in this group. The mean SUVmax of locally
positive and equivocal results was 2.1 and 1.5, respectively,
while the corresponding T/N ratios were 1.9 and 1.6.
Eleven patients of group B had a PSA value <0.8 ng/ml
at PET. Four were positive and two equivocal for a local
recurrence.
The late PET centred on the prostate bed showed five
positive and three equivocal results. In comparison to the
early PET, the late scan showed one additional equivocal
result while one early equivocal result became positive on
the late scan. When analysing the correlation of early and
late PET for local recurrence according to positive,
equivocal and negative results, a significant concordance
(p<0.001) was observed; however, the kappa coefficient
was moderate, with a value of 0.59. Mean SUVmax of the
late positive and equivocal results was 2.0 and 1.8,
respectively, while the corresponding T/N ratios were 2.1
and 1.6 (Table 4).
Endorectal MRI was performed in all 15 post-surgical
patients (Figs. 3, 4, Table 4). It was interpreted as locally
positive in 11 and suspicious in two cases. In the two
patients with negative endorectal MRI, 11C-acetate PET
was also negative in one patient and equivocal in the late
Fig. 2. 11C-acetate PET of patient 7 performed 62 months post RT.
PSA before RT was 6.3 ng/ml and it later rose again to 4.5 ng/ml at
PET, with a doubling time of 8 months. PET scan at the prostate
level (a) is shown, together with the corresponding fused imaging
(b) and CT (c). Note the focal uptake on the right, with a SUVmax of
2.7, and a smaller focus on the left, correlated with positive
endorectal MRI. Rectal activity was high in this patient
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scan in the other. Positive/equivocal results of endorectal
MRI in these patients concerned mostly a single focal
lesion. An analysis of the spatial correlation between PET
and MRI was performed according to the location of the
observed recurrence. For the nine patients with positive/
equivocal results on both examinations, a spatial correla-
tion was observed in seven (78%).
With regard to the single positive lymph node observed
by PET in patient 32, this node was negative by other
radiological criteria: ferromagnetic nanoparticle-enhanced
abdominal MRI was interpreted as negative owing to the
small size of the node (0.7 cm, measured on CT), a frank
hypo-signal and uptake of the contrast medium. Endorectal
MRI showed only a non-specific obturator lymph node
signal.
Overall, no further suspicion of metastases in group B
patients was noted except the obturator lymph node in
patient 32. Contrast-enhanced whole-body CT was nega-
tive in all patients. Complementary bone scintigraphy
performed in seven patients confirmed the suspicion of
Paget’s disease in one patient but was negative for bone
metastases. All patients were therefore amenable to salvage
RT that also encompassed the suspicious obturator lymph
node.
Fourteen patients were evaluated for PSA evolution
after salvage RT. A significant reduction in PSA by ≥50%
after salvage RT was observed in eight patients (57%).
Reduction in PSA after radiotherapy directed to the
prostate bed is, in our opinion, close to representing
proof of local tumour recurrence or residue. Of the eight
patients with positive response to RT, three had a positive
PET while in two other patients PET was equivocal. PSA
fell below the detection limit in three patients, suggesting
eradication of recurrent local disease. Interestingly, the
three patients with optimal PSA response after salvage RT
presented a PSA at RT initiation of <0.4 ng/ml (range 0.19–
0.33), underlining the need to evaluate these patients at the
earliest indication of recurrent disease. Only one patient
(no. 19) had a frankly increasing PSA value after 1 month
of RT, which was stopped and replaced by hormonal
therapy. Five patients had no significant evolution of PSA
at 6 weeks post salvage RT. One of these patients had a
PSA of 0.08 ng/ml, the clinical relevance of which remains
unclear currently.
Discussion
This study was performed in two groups of patients.
Results of 11C-acetate PET in post-RT patients showed a
high number of local recurrences. In all six patients in
whom biopsies were obtained, histology confirmed the
local recurrences. The PET results in this group of patients
presenting moderate PSAvalues are thus in agreement with
previous reports.
The second group of patients, who had initial radical
surgery, was studied at very low PSA values with a median
of only 0.4 ng/ml. Here, 11C-acetate PET was positive or
Table 3. Results of 17 group A patients treated initially with RT. Results are indicated as positive (+), equivocal (Equiv) or negative (Neg)
Pat. no. 11C-acetate PET Endorectal MRI
(spectroscopy)
Biopsy Salvage RT post
hormonal therapy
T PET
early
T PET
late
N M T SUVmax
early
T/N ratio
early
N
SUVmax
M
SUVmax
1 Equiv + Neg Neg 1.9 1.9 + + Yes
2 + + + Neg 2.4 4.0 4.4/3.0 + +
3 Neg Neg + Neg 5.8 ND
4 + Equiv Neg Neg 2.5 2.7 + + Yes
5 Equiv Equiv Neg Neg 1.6 1.3 +
6 + + Neg Neg 3.8 3.8 + + Yes
7 + + Neg Neg 2.7 2.1 +
8 + Equiv Neg Neg 2.0 2.2 +
9 + + + + 4.1 2.7 3.4/1.8 6.3 ND +
10 + + Neg Neg 2.1 1.9 ND
11 + + Neg Neg 3.9 3.3 + + Yes
12 + + Neg Neg 3.3 2.0 +
13 + + Equiv Neg 2.3 1.1 1.2 +
14 + + Neg Neg 3.0 3.0 +
15 + + Neg + 3.5 2.3 2.8 +
16 + + + Neg 3.2 1.2 2.8 ND
17 + + Neg Neg 4.1 3.4 ND
Meana 2.9 2.4
SDa 0.8 0.9
Mediana 2.9 2.3
aMean±1 standard deviation and median SUVmax and T/N ratios are given for positive and equivocal results combined
ND not done
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equivocal for local recurrence in 9 of 15 patients. Even in
the subgroup of 11 patients with PSA values <0.8 ng/ml,
evidence for local recurrence was observed in a similar
percentage. This result contrasts with the finding of a
previous study, where a sensitivity of only 7% was reported
for 11C-acetate PET in patients presenting PSA values
below 3.0 ng/ml [4].
Tumour-positive biopsies in group A and response to
RT in group B (as reflected by reduction in the PSA value)
represent the strongest evidence for local disease in these
patients. Of the patients meeting these criteria, five out of
six in group A and three out of eight in group B were
positive by PET. One further patient of group A and two
patients in group B showed equivocal PET scans. The
suboptimal percentage of PET-positive patients in group B
might be related to the limited acquisition potential of the
available PET scanner, as discussed below. The equivocal
PET scans also might be a direct consequence of this fact.
Several factors might have contributed to the better
results observed here in patients with low PSA values
compared with the aforementioned report [4]. Firstly, the
patient population studied here presented mainly stage 3
disease and positive surgical margins, highly suggestive of
local recurrent or residual disease. In comparison, patients
in the previous study presented mostly stage 2 prostate
cancer, where rising PSA was possibly more frequently
related to distant recurrence [26]. Secondly, we used image
fusion of PET with CT. We feel that it is very difficult to
evaluate small-volume areas of focal uptake in the prostate
bed region given that rectal accumulation of 11C-acetate
can be quite high. Thirdly, PET interpretation was
specifically tuned in order to deal with the expected
small-volume recurrences and consequently partial volume
effects in the post-surgical patients. This appeared com-
patible with the expected absence of residual prostate tissue
and absence of any post-surgical inflammatory response.
In the follow-up of the post-surgical patients, histolog-
ical confirmation of local recurrence was not performed,
mainly for two reasons: first, the indication for salvage RT
was supported sufficiently by the available data; second,
the risk of a negative biopsy result was high in the presence
of very limited disease. However, in these patients PSA
decrease after salvage RT was taken as a safe indication of
local tumour response. This interpretation is supported by
the fact that after radical surgery, PSA values as low as
0.1 ng/ml most reliably reflect prostate cancer recurrence
and/or residual disease [22]. In this respect, the single
patient evaluated and re-treated at a PSA below 0.1 ng/ml
(patient 28) should be interpreted with caution, since the 3-
year survival rate without further increase in PSA in such
patients may be as high as 33% [22].
Fig. 3. 11C-acetate PET of patient 23, performed 24 months post
surgery. The pre-surgical PSA value of 13.2 ng/ml fell to 0.06 ng/ml
before rising again to 0.26 ng/ml at PET. Prostate bed-centred PET
scan (a) is shown, together with corresponding fused PET-CT
(b) and endorectal MRI (c). Note the small area of focal uptake
with a SUVmax of 2.6. The focal PET uptake correlated with an
endorectal MRI finding suspicious for a recurrence close to the
urethral anastomosis. Salvage RT was rapidly initiated within
1 month of 11C-acetate PET and resulted in a decrease in PSA to
0.06 ng/ml 6 weeks after RT termination
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The significance of stable (four patients) or rising PSA
(one patient) after salvage RT in the remaining post-
surgical patients remains unclear currently. Presence of
minor distant disease cannot be excluded. However, since
PSA was measured only 6 weeks after RT, the PSA
response could not be evaluated with certainty.
Given the high number of group A patients who were
positive for local tumour recurrence on PET (many of these
results being confirmed by histology), one might argue that
in such patients 11C-acetate PET could be performed earlier
in the course of suspicious PSA measurements. On the
other hand, it needs to be borne in mind that, particularly in
younger patients, normal prostate tissue takes up 11C-
acetate in significant amounts [37]. However, it is not
known to what degree normal prostate tissue of older
patients in the post-RT situation accumulates 11C-acetate,
in particular after a long delay post RT. Our PET results
clearly showed the presence of focal uptake while the
background activity of normal prostate tissue was below
SUVmax 2, as shown by the T/N ratios.
PET was positive or equivocal for metastases in six
patients of group A. These observations concerned mostly
lymph node metastases, several of which were confirmed
by CT. Another obturator lymph node was positive on PET
in group B. Overall, three lymph nodes less than 1 cm in
diameter were positive or equivocal on PET despite being
unsuspicious by radiological criteria. However, it has not
yet been possible to confirm these results, the follow-up
being too short to date.
Despite the positive observations concerning lymph
node disease, the sensitivity of PET for detection of distant
disease appeared limited, notably for osseous metastases.
This limited ability to detect distant metastases might have
been partially related to the significant tracer uptake in the
pancreas, intestinal tract and bone marrow in some patients.
Focal uptake was also observed in degenerative bone and
joint disease. Furthermore, the limited resolution of the
available PET and the need to fuse PET with CT from a
different machine might have contributed to a sub-optimal
detection rate of metastases.
With regard to optimisation of the PET scanning time,
tumour recurrences remained positive or equivocal in the
large majority of patients at the late scanning time, two
physical half-lives after the injection of 11C-acetate.
However, this study was not designed to identify the
optimal timing for scanning. Dynamic scanning has been
proposed previously [26]. Recently, in another study, 18F-
fluorocholine PET was investigated in the staging of
primary prostate cancer. Results showed that late PET,
performed 1 h after injection, allowed better differentiation
Fig. 4. 11C-acetate PET of patient 31 performed 14 months post
surgery. The pre-surgical PSA value of 5.5 ng/ml fell to <0.04 ng/ml
after surgery before rising again to 0.20 ng/ml at PET. Early PET
scan at the upper bulb level (a) is shown, together with the
corresponding CT (b) and fused imaging (c) as well as endorectal
MRI (d). Note the small area of focal uptake with a SUVmax of 2.7.
The focal PET uptake correlated with the positive endorectal MRI
for a small recurrence at the upper side of the penile bulb. Salvage
RT was initiated within 40 days of 11C-acetate PET and resulted in a
decrease in PSA to 0.10 ng/ml 6 weeks after RT termination
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between benign and malignant prostate tumours when
compared with early imaging [38].
Two other recent studies addressed the value of
integrated 18F-fluorocholine PET/CT in patients with
biochemical relapse when PSA values are less than 5 ng/
ml [39, 40]. Both studies showed the feasibility of
fluorocholine PET at these PSAvalues, with a high number
of positive findings. In comparison, in the group of post-
surgical patients evaluated here, PSAwas <0.8 ng/ml in 11
patients. Despite the very low PSA values, 11C-acetate was
positive or equivocal in the majority of these patients.
Further studies are therefore warranted to establish the
value of 11C-acetate based on integrated PET/CT instru-
mentation and to compare these results with those obtained
using 18F-fluorocholine.
Conclusion
The results of this study show that 11C-acetate PET may
have significant potential for the detection of recurrent
prostate cancer, most notably in the very early work-up of
post-surgical patients. While in group A the number of
locally positive PET studies was very high, suggesting that
the examination was performed too late, in group B the
number of positive patients was slightly lower, suggesting
a limited sensitivity that might be improved in future
evaluations. Some limitations were observed in this study
that may have been related in part to the available PET
scanner. While performance of the machine was tuned to a
maximum, its acquisition potential remained limited by
saturation, and in addition the resolution might have been
lower than on modern PET/CT equipment. Further
improvement might be obtained by PET/CT co-registration
and by optimisation of scanning time, as indicated by the
results shown here in the late pelvic scan. This study
therefore shows, in contrast to a previous one, that 11C-
acetate PET may be of interest particularly in patients
presenting very low PSA values following initial radical
surgery, and possibly also earlier when there is a suspicious
increase in PSA post RT. These situations might merit
further evaluation of 11C-acetate PET using more advanced
PET/CT instrumentation.
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Table 4. Results of 15 group B patients treated initially with radical surgery. Results are given as positive (+), equivocal (Equiv) or negative
(Neg)
Pat. no. 11 C-acetate PET Endorectal MRI Salvage RT (Gy) PSA post RTa
T PET early T PET late N/M T SUVmax early T/N ratio early
18 Neg Neg Neg/Neg – + 67 ↔
19 Equiv + Neg/Neg 1.0 1.4 + Stoppedb ↑
20 Neg Neg Neg/Neg – + 74 ↔
21 Neg Neg Neg/Neg – + 74 ↓↓
22 Equiv Equiv Neg/Neg 2.3 1.8 + 74 ↓
23 + + Neg/Neg 2.6 2.2 Equiv 74 ↓
24 Neg Neg Neg/Neg + 74 ↓↓
25 Equiv Neg Neg/Neg 1.2 1.7 + 74 ↓
26 + + Neg/Neg 1.8 1.6 + 74 ↓
27 Neg Equiv Neg/Neg Neg 64 ↔
28 + + Neg/Neg 2.0 2.0 + 74 ↔
29 Equiv Equiv Neg/Neg 1.4 1.3 + Ho+RTc
30 Neg Neg Neg/Neg Neg 64 ↓↓
31 + Neg Neg/Neg 2.7 1.9 + 74 ↓
32 + + +/Neg 1.6 1.7 Equiv 74 ↔
Meand 2.1/1.5 1.9/1.6
SDd 0.5/0.6 0.2/0.2
Mediand 2.0/1.3 1.9/1.6
aPSA evolution after RT is shown: a decrease or increase by ≥50% in PSA 6 weeks post therapy compared with the initial value is indicated
by ↓ and ↑, respectively. A PSA decrease to below the detection limit (0.04 ng/ml) after salvage RT is indicated by ↓↓. PSA variations
of <50 % are denoted by ↔
bSalvage RT was interrupted because of a significant increase in PSA after 1 month therapy
cPatient 29 presented a highly aggressive tumour (Gleason 5+5). He was re-treated with anti-hormonal therapy followed by RT and was
therefore not evaluated for PSA evolution
dMean, 1 SD and median results are each given as two numbers for lesions interpreted as frankly positive or equivocal, respectively
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